- Report
- May 2024
- 129 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- June 2024
- 200 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1185EUR$1,250USD£990GBP
- Report
- October 2024
- 97 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- May 2022
- 55 Pages
Global
From €1896EUR$2,000USD£1,584GBP
Meningioma is a type of brain cancer that affects the membranes surrounding the brain and spinal cord. Treatment for meningioma typically involves surgery, radiation therapy, and chemotherapy. Drug therapy is also used to treat meningioma, and the meningioma drug market is composed of a variety of drugs used to treat the disease. These drugs include corticosteroids, anticonvulsants, and anti-angiogenic agents. Corticosteroids are used to reduce inflammation and swelling, while anticonvulsants are used to control seizures. Anti-angiogenic agents are used to inhibit the growth of new blood vessels, which can help reduce tumor growth.
The meningioma drug market is highly competitive, with a number of companies offering various treatments. Some of the major players in the market include Novartis, Pfizer, Merck, and Roche. Other companies such as Bristol-Myers Squibb, Eli Lilly, and AstraZeneca also offer treatments for meningioma. Show Less Read more